Procollagen I Intact N-Terminal, Serum
Use
This test is useful for aiding in monitoring antiresorptive and anabolic therapy in patients with osteoporosis, and serves as an adjunct in the assessment of conditions associated with increased bone turnover, such as Paget's disease. Procollagen type I propeptides, specifically PINP, reflect the synthesis rate of collagen type I, making it a sensitive marker for bone formation. It is recommended that the test be performed at baseline before starting osteoporosis therapy and again 3 to 6 months later. The assay is specific for the intact trimeric form of PINP, and a change of 21% or more from baseline PINP levels after 3 to 6 months of therapy indicates an adequate therapeutic response.
Special Instructions
Not provided.
Limitations
Diurnal variation exists for procollagen I intact N-terminal propeptide (PINP) levels, with values higher at night. Clearance might be affected in individuals with severe liver disease, leading to elevated PINP levels. Rare cases of human anti-mouse antibodies (HAMA) or heterophile antibodies may cause interference in immunoassays, and results must be interpreted cautiously if they do not correlate with clinical presentation.
FDA ApprovedNew York Approved
Methodology
Immunoassay (RIA)
Biomarkers
Procollagen I Intact N-Terminal Propeptide (PINP)
Protein
LOINC Codes
- 47255-5 - PINP SerPl-mCnc
- 47255-5 - PINP SerPl-mCnc
Result Turnaround Time
2-6 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.25 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia, or gross icterus will result in rejection.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 7 days |
| Frozen | 180 days |